São Paulo Health Department studies dispensing cannabidiol for multiple sclerosis; department does not confirm deadline

The São Paulo State Health Department (SES) informed Sechat that the inclusion of multiple sclerosis in the state protocol for dispensing cannabidiol-based products is in the study phase. The department did not confirm the information that the final protocol would be presented by December 2025, a possibility that had been raised by the sector last week.

If the measure is consolidated after the technical analysis, the goal is to allow the distribution of cannabidiol to patients with multiple sclerosis in the public network of São Paulo starting in 2026. This inclusion would represent a significant expansion in the care for patients in need of cannabinoid therapy.

The expansion of access to cannabidiol is an expectation of State Deputy Caio França (PSB), author of State Law 17,618/23. The legislation established the policy of free provision of cannabis-based medicines in the state of São Paulo.

According to the deputy's office, the document being prepared should establish the clinical access criteria and guidelines for medical prescription. It is expected that a final meeting of a Working Group (WG) will take place to consolidate the technical approval before submission for validation by the state Health Secretary.

Current distribution of cannabidiol in the public network

In a statement, SES emphasized that the Unified Health System (SUS) already provides cannabidiol-based medicines in São Paulo. Distribution takes place through the Specialized Component of Pharmaceutical Assistance (CEAF).

The current protocol, operational since 2024, includes treatment with cannabidiol for three specific conditions:

Dravet Syndrome;

Lennox-Gastaut Syndrome;

Tuberous Sclerosis Complex.

How to access treatment with cannabidiol

For patients who fit the diagnoses already covered by current legislation, access to cannabidiol requires compliance with rigorous administrative and clinical steps. It is necessary to present a medical prescription issued by a qualified professional and sign the Informed Consent Form (ICF).

The withdrawal of supplies is carried out at reference municipal pharmacies. The use of products follows the safety and efficacy standards established by the National Health Surveillance Agency (Anvisa), ensuring the quality of the treatment offered.